<DOC>
	<DOC>NCT00322452</DOC>
	<brief_summary>The purpose of this study is to compare gefitinib with carboplatin / paclitaxel doublet chemotherapy given as first line treatment in terms of progression free survival in selected NSCLC patients with the objective of demonstrating non-inferiority.</brief_summary>
	<brief_title>First Line IRESSAâ„¢ Versus Carboplatin/Paclitaxel in Asia</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Locally advanced Stage IIIB not amenable to local therapy or Stage IV (metastatic) NSCLC with adenocarcinoma histology. Never smokers or light exsmokers.(ceased smoking at least 15 years before Day 1 of study treatment and 10 packyears or fewer) Had prior chemotherapy, biological (including targeted therapies such as EGFR and vascular epidermal growth factor (VEGF) inhibitors) or immunological therapy. Preexisting idiopathic pulmonary fibrosis evidence by CT scan at baseline.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Gefitinib</keyword>
</DOC>